Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.Monte Rosa announced a collaboration with Novartis AG NVS to develop novel degraders for immune-mediated diseases.Under the terms of the agreement, Monte Rosa will receive an upfront payment of $120 million. Monte Rosa will also receive payments to maintain the options.In total deal value, Monte Rosa is eligible to receive up to ...

2025年9月15日Monte Rosa Therapeutics宣布与诺华合作开发降解剂治疗免疫介导性疾病， Mont e Ro s a The r apeuti c s （Na sdaq: GLUE）开盘大涨4 9 . 2 7%！ 9月15日， 马萨诸塞州波士顿，开发新型分子胶降解剂（MGD）药物的临床生物技术 公司 Mont e Ros a The r a pe uti c s （Na s da q: GLUE）宣布与诺华公司合作开发用于免疫介导疾病的新 型降解剂。除了202 4年10月宣布的Mont e Ros a VAV1降解剂（ 包括MRT- 6160）的全球独家许 可协议外，此次合作是 Mont e Ros a 与诺华公司的第二份合作 协议。 | | Global license agreement to advance | Collaboration with Novartis for | Strategic collaboration to discover | | --- | --- | --- | --- | | | VAV1-directed molecular qlue | | no ...

Summary of Monte Rosa Therapeutics Conference Call Company Overview - Monte Rosa Therapeutics is a relatively young company, approximately six to seven years old, focused on targeted protein degradation, particularly molecular glue degraders [2][3] - The company has developed a platform named "Queen" for creating a portfolio of assets, with three currently in clinical trials, focusing on immunology and inflammation (I&I) as well as oncology [2][3] Recent Developments - Monte Rosa announced a new collaboration with Novartis, extending their previous partnership related to their lead asset MRT-6160, which targets a signaling protein downstream of T-cell and B-cell receptors [3][4] - The partnership reflects mutual respect and aims to explore various autoimmune diseases driven by TH17 [4] Molecular Glue Degraders vs. PROTACs - Molecular glue degraders bind to ubiquitin ligases, inducing protein-protein interactions without needing specific pockets on the target proteins, unlike PROTACs which require binding to a druggable pocket [5][6][7] Key Targets and Programs - **VEF1 Target**: - VEF1 is a significant target in I&I, historically challenging to drug due to its lack of a good binding pocket [9][10] - Preclinical studies show that knockout mice lacking VEF1 are protected from autoimmune diseases, validating its potential as a therapeutic target [10][11] - The company has not observed any toxicities in their GLP toxicology studies, indicating a favorable safety profile [11][12] - **Next7 Target**: - Next7 is positioned at the top of the NLRP3 inflammasome pathway, crucial for assembling the inflammasome, which is linked to various inflammatory diseases [19][20] - The degradation of Next7 is expected to provide a more effective and safer therapeutic approach compared to existing biologics like Canakinumab [20][21] Clinical Development and Future Steps - The company is confident in selecting phase two doses based on positive phase one results, with no safety concerns and effective degradation of VEF1 observed [16][17] - Next steps include initiating phase two trials, requiring sufficient material and FDA protocol clearance [17][18] Indication Selection and Market Strategy - Monte Rosa is focusing on large, high-value indications for VEF1 while exploring smaller indications for Next7, leveraging partnerships to enhance development capabilities [28][29] - The company is also considering opportunities in oncology, with a flexible resource allocation strategy based on potential rather than fixed percentages [29] Financial Position - Monte Rosa received $120 million upfront from the Novartis deal, which is expected to extend their cash runway, previously reported to be just below $300 million, into 2028 [34][36] Partnerships - The partnership with Roche differs from Novartis, focusing on discovery with Roche nominating targets for Monte Rosa to screen [33] Conclusion - Monte Rosa Therapeutics is strategically positioned in the biotech space with innovative approaches to drug development, strong partnerships, and a clear focus on high-potential therapeutic targets in both I&I and oncology [2][3][28]

格隆汇9月15日｜Monte Rosa(GLUE.US)盘前暴涨57%，公司与诺华制药达成57亿美元授权合作协议。 ...

此次合作是两家公司之间的第二次合作。去年，双方已就MRT-6160达成协议，该药物目前正处于治疗 自身免疫及炎症疾病的早期临床试验阶段。 这项协议也是诺华制药本月达成的第二笔大型交易。在此之前，诺华制药刚刚与舶望制药(Argo Biopharmaceutical)签署了一项高达52亿美元的合作协议，用于开发实验性心脏病药物。 周一，瑞士制药商诺华制药(NVS.US)与药物研发公司Monte Rosa Therapeutics(GLUE.US)签署了一项价 值高达57亿美元的授权合作协议，以共同开发用于免疫介导疾病的药物。根据协议，Monte Rosa将获得 1.2亿美元的预付款，并有机会通过里程碑付款和销售分成获得额外收益，使交易总额最高达到57亿美 元。受此消息提振，截至发稿，Monte Rosa周一美股盘前暴涨超53%。 据悉，免疫介导疾病是指免疫系统错误攻击健康组织，从而引发炎症和损伤。这类难以治疗的疾病会严 重影响患者的生活质量。双方达成的协议赋予诺华制药对一个未公开的药物发现靶点的独家权利，并提 供从Monte Rosa早期免疫学管线中另外两个研发项目获得许可的选择权。 Monte Rosa将利用其 ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. ...

Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales Extended cash runway enables Monte Rosa to accelerate preclinical and clinical-stage i ...

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, Sep ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the quarterly period ended June 30, 2025 OR ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) (I.R.S. Emplo ...

Phase 1/2 study of GSPT1-directed MGD MRT-2359 advancing in heavily pretreated, castration-resistant prostate cancer patients; additional results on track for H2 2025 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic appr ...